The Vertical Group
This article was originally published in Start Up
Executive Summary
The Vertical Group sticks closely to medical device investments, because that's the industry its partners know best. Although it has a narrow industry focus, its flexibility allows it to thrive in good times and bad. It runs an evergreen fund, of which general partners and its two special limited partners own 50%. And it has a great deal of investment flexibility as well; it can invest in all stages of a company, from seed stage to the aftermarket, where it can hold both long and short positions.
You may also be interested in...
The Risks of Surgical Over-Reaching
The announcement this month that HeartPort Inc. will be acquired by Ethicon Inc., a Johnson & Johnson operating company, turns a kind of final page on what was, to anyone living through the crazy world of medical device start-ups over the past several years, one of the industry's most interesting stories. In the end, what has become clear, is that HeartPort simply made the wrong bet. The cardiac surgery revolution, if you can call it that, has been a shift from CPB to off-pump procedures; about minimally invasive techniques per se, surgeons are still very ambivalent.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.